GoHealthcare MSK Specialty Procedure Library

Basivertebral Nerve Ablation

Intraosseous basivertebral nerve ablation for chronic vertebrogenic low back pain - prior authorization, medical necessity, coverage, coding, and reimbursement operations.

Developed by Pinky Maniri, Founder and Chief Executive Officer, GoHealthcare Practice Solutions

Request HelpView Case Studies

Procedure CategoryVertebral Augmentation and Ablation

Operational FocusMedical necessity, payer policy, prior authorization, coding, reimbursement, and denial prevention

Coding Reference Year2026 - verify current codes and payer policy before use

GoHealthcare Operational Results

98%Company-reported prior authorization approval rate

50 StatesNational prior authorization and utilization-management support

MSK FocusPain, spine, orthopedics, PM&R, and ambulatory surgery center operations

Company-reported performance. Results vary by client, payer, specialty, documentation quality, benefit design, and case mix. No authorization or payment outcome is guaranteed.

Operational use: This page is designed for physicians, APPs, prior authorization teams, utilization-management nurses, coding and revenue-cycle professionals, ASCs, hospitals, and healthcare executives. It is not a procedural technique manual. Always verify the controlling policy and code set for the individual patient and date of service.

Page Contents

Use the links below to move directly to the clinical, payer, documentation, coding, reimbursement, and denial-management sections.

Clinical and Coverage Foundation

1. Overview
2. Evidence at a Glance
3. Procedure Overview
4. Relevant Anatomy
5. Clinical Indications
6. Patient Selection
7. Contraindications and Precautions
8. Medical Necessity
9. Conservative Treatment Requirements
10. Diagnostic Prerequisites and Treatment Sequencing
11. CMS National Coverage Determinations and National Guidance
12. Medicare LCDs, Billing and Coding Articles, and MAC Guidance

Payer, Documentation, Coding and Revenue

13. Commercial Payer Policies and Guidelines
14. Delegated Utilization-Management Guidelines
15. Evidence-Based Clinical and Specialty-Society Guidelines
16. Policy and Guideline Comparison Matrix
17. Prior Authorization Requirements
18. Documentation Requirements
19. Documentation Pearls
20. CPT and HCPCS Coding
21. ICD-10-CM Crosswalk
22. Billing Integrity: Modifiers, Units, NCCI, MUE, and Place of Service
23. Reimbursement Considerations
24. Denial Prevention

Denials, Operations and Resources

25. Common Denial Reasons
26. Appeals, Reconsideration, and Peer-to-Peer
27. Operational Workflow
28. Payer Perspective
29. Clinical Pearls
30. GoHealthcare Perspective
31. GoHealthcare Insights
32. Frequently Asked Questions
33. GoHealthcare Case Study
34. Related Procedures and Resources
35. References and Reading Recommendations
36. Standard Disclaimer

01

Foundation

Overview

Basivertebral nerve ablation is an implant-free radiofrequency treatment for chronic vertebrogenic low back pain associated with Type 1 or Type 2 Modic changes at L3-S1. The central operational risk is its narrow coverage profile: the record must align the pain pattern, MRI findings, failed conservative care, treated levels, frequency limits, and Medicare KX attestation before scheduling and billing.

GoHealthcare operational objective

Align the clinical record, payer policy, authorization, scheduled service, coding, and claim before the procedure occurs. This reduces avoidable delays, peer-to-peer escalation, denials, and post-payment exposure.

Back to page contents

02

Foundation

Evidence at a Glance

Intraosseous basivertebral nerve ablation (BVNA) is an image-guided, implant-free, minimally invasive procedure that uses radiofrequency energy to thermally destroy the basivertebral nerve (BVN) within the vertebral body, interrupting transmission of chronic vertebrogenic low back pain. Unlike vertebroplasty and kyphoplasty, which stabilize a fracture, BVNA treats a distinct pain generator: degenerated vertebral endplates evidenced by Type 1 or Type 2 Modic changes on MRI. The best-known system is the Intracept(R) Procedure; the device market now also includes Stryker OptaBlate(R) BVN and Merit Medical ViaVerte(R).

Domain	Summary Position (verify per payer / date of service)
Medicare NCD	No National Coverage Determination for BVNA (Medicare has no NCD for non-facet joint interventions).
Medicare LCD	Noridian twin LCDs L39642 (Jurisdiction JE) and L39644 (Jurisdiction JF), both effective 01/28/2024, with companion Billing and Coding Articles A59466 and A59468. A 03/05/2026 revision applies; NGS has a proposed policy in development (DA60324). Criteria are highly specific and largely uniform.
Commercial coverage	Increasingly covered as medically necessary with criteria that mirror the Medicare LCD (BCBS plans, and Medicare Advantage plans adopting the Noridian LCDs). Some commercial plans still treat out-of-criteria BVNA as investigational; verify the specific policy and edition.
Evidence level	Supported by a sham-controlled RCT (SMART; Fischgrund, Eur Spine J 2018) with 2- and 5-year durability, and a standard-care-controlled RCT (INTRACEPT; Khalil/Smuck/Koreckij, Spine J 2019). LCD reviewers characterized the evidence as moderate-quality and found BVNA effective versus sham and superior to continued standard care.
Image guidance	Fluoroscopic (77003) and CT (77012) guidance are inherent and bundled into 64628/64629 (not separately reportable).
Prior authorization	Commonly required by commercial and Medicare Advantage plans; frequently delegated to eviCore, Carelon, or TurningPoint. Traditional Medicare does not prior-authorize but enforces strict LCD criteria and requires the KX modifier to attest compliance.
Conservative therapy	A genuine, documented failure of at least 6 months of non-surgical management (generally at least 3 modalities) is required - a real prerequisite, unlike the acute-fracture augmentation pathway.
Key imaging	MRI demonstrating Type 1 or Type 2 Modic changes at the vertebral endplates between L3 and S1 is the single decisive coverage element.
Coding snapshot	64628 (first 2 vertebral bodies, lumbar or sacral) and +64629 (each additional vertebral body). Image guidance bundled. Medicare requires the KX modifier; modifier 52 applies if only one body/one endplate is treated.
Frequency limits (Medicare)	L3-S1 only; once per named vertebral body per lifetime; no more than 4 vertebral bodies per beneficiary lifetime; no more than 2 levels per session; may not be combined with facet or epidural intervention in the same session.

Back to page contents

03

Clinical Foundation

Procedure Overview

Chronic low back pain (CLBP) has many potential sources. Vertebrogenic pain is a specific, increasingly recognized subtype originating from damaged vertebral endplates rather than from the disc, facet joints, or nerve roots. The basivertebral nerve travels within the vertebral body and carries nociceptive signals from the endplates; when the endplates degenerate - a process visualized as Type 1 or Type 2 Modic changes on MRI - the result can be deep, midline, axial low back pain that is characteristically worse with sitting, bending, and axial loading. BVNA is an implant-free, minimally invasive, typically outpatient procedure in which access instruments create a path to the basivertebral nerve trunk and radiofrequency energy is applied to thermally ablate it. Because no hardware is left behind, there is no device-related MRI conditionality concern, and the vertebral body remains available for future

imaging. The procedure targets the L3 through S1 vertebral bodies, where the treatable BVN anatomy and the supporting evidence are concentrated. This guide is written for the teams that must consistently obtain authorization and clean reimbursement: physicians and advanced practice providers who document, prior authorization and utilization management staff who submit and defend requests, revenue cycle and coding professionals, and ASC / hospital outpatient department leaders. BVNA carries unusually specific coverage criteria and strict lifetime frequency limits, so documentation precision and coding discipline - including the KX modifier on Medicare claims - are decisive.

Back to page contents

04

Clinical Foundation

Relevant Anatomy

Only anatomy relevant to selection, medical necessity, and documentation is summarized. The vertebral body is the anterior weight-bearing element of the vertebra; its superior and inferior surfaces are the endplates that interface with the intervertebral discs.

• Vertebral endplates are the pain-relevant structures. Endplate degeneration and the associated marrow changes (Modic changes) are the substrate of vertebrogenic pain.
• Basivertebral nerve (BVN) enters the posterior vertebral body through the basivertebral foramen and branches toward the endplates; its main trunk within the vertebral body is the therapeutic ablation target.
• L3 through S1 vertebral bodies are the covered treatment region; the evidence base and the coverage criteria are confined to these levels.
• Adjacent neural structures (nerve roots, spinal canal) are relevant to procedural safety and to excluding radicular or stenotic pain as the dominant, non-vertebrogenic pain source.

Back to page contents

05

Clinical Foundation

Clinical Indications

BVNA is indicated for chronic vertebrogenic low back pain in appropriately selected, skeletally mature patients whose imaging and clinical picture point to the vertebral endplate as the pain generator. The recognized indication profile is narrow and specific:

• Chronic low back pain of at least 6 months' duration, with axial low back pain as the dominant symptom.
• Failure to improve despite documented non-surgical management of at least 6 months (generally at least 3 modalities).
• MRI demonstrating Type 1 or Type 2 Modic changes at the vertebral endplates between L3 and S1, correlating with the clinical presentation.
• Absence of another dominant pain source (radiculopathy, symptomatic stenosis, deformity, fracture, tumor, or infection) that would better explain the symptoms.

GoHealthcare Clinical Insight

Vertebrogenic pain has a recognizable clinical signature: deep, midline, axial low back pain that worsens with sitting and forward flexion and improves with recumbency. Documenting that pattern alongside the Modic finding builds the tightest possible indication narrative and is what distinguishes a covered BVNA candidate from generic chronic low back pain.

Back to page contents

06

Clinical Foundation

Patient Selection

Selection is unusually criteria-driven for BVNA because both the evidence and the coverage policies define a narrow eligible population. Documentation should affirmatively establish each element.

• Skeletally mature adult (18 years or older).

• Chronic (6 months or longer) axial-dominant low back pain refractory to at least 6 months of conservative care.
• MRI Type 1 or Type 2 Modic changes at L3-S1 endplates correlating with the clinical level.
• Vertebrogenic pain pattern on history and examination (axial, midline, worse with loading/sitting).
• Exclusion of competing dominant pain generators (radicular, stenotic, deformity, fracture, tumor, infection) by history, examination, and imaging.
• Physical and psychological ability to tolerate and benefit from the procedure.

Back to page contents

07

Clinical Foundation

Contraindications and Precautions

The BVNA contraindication list is both clinical and, importantly, a coverage-exclusion list; several of these conditions render the procedure non-covered under the Medicare LCDs.

• Skeletal immaturity (under 18 years of age) - non-covered.
• Dominant radicular pain, symptomatic spinal stenosis, or neurogenic claudication - the pain source is not vertebrogenic; non-covered.
• Metabolic bone disease or osteoporosis, metastatic tumor, or other vertebral pathology (fracture, infection, deformity, prior surgical change at the level) that could cause the symptoms or complicate the procedure - generally non-covered/precluded.
• Active local or systemic infection, uncorrectable coagulopathy, or inability to undergo the procedure safely.
• Imaging suggesting an alternative etiology for the low back pain on MRI, flexion/extension radiographs, or CT.

Back to page contents

08

Coverage and Medical Necessity

Medical Necessity

Medical necessity for BVNA rests on a tight convergence of a vertebrogenic pain pattern, a failed conservative-care trial of adequate duration, and MRI Modic changes at L3-S1 - with affirmative exclusion of competing pain generators. Because the eligible population is narrow, the record must speak to each element explicitly.

Elements that consistently establish medical necessity

• Chronic (6 months or longer) axial-dominant low back pain with a documented vertebrogenic pattern.
• Failure of at least 6 months of conservative care, with the specific modalities and outcomes listed.
• MRI Type 1 or Type 2 Modic changes at L3-S1 endplates correlating with the treated level.
• Affirmative exclusion of radicular, stenotic, deformity, fracture, tumor, and infectious etiologies.
• Skeletal maturity and the physical/psychological ability to benefit.
• A level-specific medical-necessity statement, and (for Medicare) attestation supporting the KX modifier and the lifetime/session frequency limits.

Back to page contents

09

Coverage and Medical Necessity

Conservative Treatment Requirements

In contrast to acute-fracture augmentation, BVNA requires a genuine, well-documented conservative care trial. Most policies require failure to improve after at least 6 months of non-surgical management, generally spanning at least three modalities. The record should specify what was tried, for how long, and the response.

• Activity modification and avoidance of aggravating activities.
• Physical therapy, a structured/home exercise program, and low-impact conditioning.
• Pharmacotherapy appropriate to the presentation.
• Interventional or adjunctive measures where indicated (for example, epidural or facet injection therapy) and their outcomes.
• Other supportive measures (heat/cold, cognitive/behavioral support) as applicable.

GoHealthcare Prior Authorization Insight

The conservative-care requirement is a hard gate for BVNA, not a formality. Requests are commonly pended for a conservative history that is vague on duration or modality count. State plainly that the patient failed at least 6 months of care and enumerate the specific modalities and their results.

Back to page contents

10

Coverage and Medical Necessity

Diagnostic Prerequisites and Treatment Sequencing

MRI is the linchpin of BVNA coverage. The decisive finding is Type 1 or Type 2 Modic change at the vertebral endplates between L3 and S1. Imaging must also exclude alternative pathology.

Understanding Modic changes

• Type 1 (inflammatory/edematous): endplate/marrow signal that is hypointense on T1-weighted images and hyperintense on T2-weighted images, reflecting edema and vascularized fibrous tissue.

• Type 2 (fatty): replacement of normal marrow by fat, appearing hyperintense on T1-weighted images (and typically iso- to hyperintense on T2), reflecting a more chronic, stable change.
• Both Type 1 and Type 2 are covered indications for BVNA; the change must involve the endplates between L3 and S1 and correlate with the treated level.

Supporting and exclusionary imaging

• MRI to confirm Modic changes and to exclude tumor, infection, fracture, or canal compromise.
• Flexion/extension radiographs and/or CT where needed to exclude instability, deformity, or an alternative etiology.
• Documentation that the imaging findings correlate with the clinical presentation at the treated level(s).

Back to page contents

11

Medicare Policy

CMS National Coverage Determinations and National Guidance

CMS has no procedure-specific National Coverage Determination for intraosseous basivertebral nerve ablation. Medicare coverage is therefore controlled by the applicable Medicare Administrative Contractor, the effective Local Coverage Determination, and its companion Billing and Coding Article for the beneficiary's jurisdiction and date of service.

National coverage rule

No procedure-specific NCD does not mean automatic coverage or automatic noncoverage. The applicable MAC policy, benefit category, documentation, and reasonable-and-necessary standard remain controlling.

Back to page contents

12

Medicare Policy

Medicare LCDs, Billing and Coding Articles, and MAC Guidance

There is no National Coverage Determination for BVNA. Coverage is administered by Medicare Administrative Contractors through Local Coverage Determinations and their companion Billing and Coding Articles. Noridian maintains twin LCDs - L39642 (Jurisdiction JE) and L39644 (Jurisdiction JF), both effective 01/28/2024 - with companion articles A59466 and A59468; a revision applies as of 03/05/2026, and NGS has a proposed policy in development (DA60324). The criteria below synthesize the common Noridian positions. Do not reproduce policy language verbatim; read the LCD that applies to the patient's MAC jurisdiction and date of service.

Coverage criteria (synthesized)

• Skeletally mature patient with chronic low back pain of at least 6 months, with lower back pain as the dominant symptom.
• Failure to adequately improve despite documented non-surgical management of at least 6 months (generally at least 3 modalities).
• MRI Type 1 or Type 2 Modic changes at the endplates between L3 and S1.
• Absence of additional vertebral pathology (fracture, tumor, infection, deformity, trauma, post-surgical change) that could cause the symptoms or complicate the outcome.
• Physical and psychological assessment of the patient's ability to tolerate and benefit from the procedure.

Frequency limits and non-coverage (Medicare)

• Treatment is limited to vertebral bodies L3-S1; each named vertebral body is covered once per lifetime, with no more than 4 individual vertebral bodies treated per beneficiary per lifetime.
• No more than 2 vertebral levels may be treated in a single session.

• BVNA may not be combined with any other paravertebral injection or intervention (facet or epidural) in the same session.
• Prior BVNA of a named vertebral body precludes coverage of that same body again.
• Non-covered for skeletal immaturity (under 18) and for the contraindicated conditions above (including osteoporosis/metabolic bone disease, metastatic tumor, neurogenic claudication, and radicular symptoms) absent a documented explanation of precautionary measures.
• The KX modifier must be appended to the covered CPT code to attest that all LCD requirements are met.

GoHealthcare Clinical Insight - Medicare

Traditional Medicare does not prior-authorize BVNA, but the LCD criteria and the lifetime frequency cap are enforced at adjudication and on audit - and the KX modifier is a formal attestation that every requirement is met. Treat the KX modifier as a compliance commitment: only append it when the Modic finding, the 6-month conservative-care failure, the level, and the lifetime/session limits are all documented in the record.

Back to page contents

13

Payer Policy

Commercial Payer Policies and Guidelines

Commercial coverage is plan-, product-, jurisdiction-, and effective-date-specific. The table below includes representative commercial payer positions from the source guide; verify the live policy and member benefits before submission.

Payer / Vendor	PA Pathway	Representative Position (verify current policy)
TurningPoint Healthcare Solutions	PA via TurningPoint (per plan)	Manages BVNA for certain plans (for example, some Blue Cross Blue Shield programs); criteria track the LCD framework.
UnitedHealthcare	PA per plan; MA adopts LCD	UnitedHealthcare Medicare Advantage applies the Noridian LCDs (L39642/A59466, L39644/A59468); commercial coverage is governed by the applicable medical policy.
Aetna	PA / precertification per plan	CPB 0016 (Back Pain: Invasive Procedures) addresses the Intracept System (intraosseous basivertebral nerve ablation). Aetna's determination has been evolving; verify the current medically-necessary versus experimental status for the indication.
Blue Cross Blue Shield plans	PA per plan; some vendor-managed	Multiple BCBS plans cover BVNA for patients 18 and older meeting Modic-change and conservative-care criteria, with lifetime caps mirroring Medicare (for example, no more than 4 vertebral bodies per lifetime; treatment of 3 or more bodies in one session and retreatment of a previously treated body may be deemed investigational or not medically necessary).
Humana	PA per plan / MA	Covers BVNA for qualifying vertebrogenic pain; MA plans apply the applicable LCD and internal coverage policy.

Back to page contents

14

Utilization Management

Delegated Utilization-Management Guidelines

Delegated utilization-management entities apply clinical review criteria on behalf of specific payer products. Delegation must be verified for the individual member; the UM vendor does not independently establish the member benefit or guarantee claim payment.

Payer / Vendor	PA Pathway	Representative Position (verify current policy)
eviCore (Cigna and delegated plans)	PA via eviCore MSK	BVNA is reviewed under eviCore's musculoskeletal guidelines; eviCore's ablation/denervation guidance (CMM-208, Ablation/Denervation of Joints and Peripheral Nerves; a V1.0.2026 edition effective 08/04/2026) addresses basivertebral nerve ablation. Confirm the specific guideline and edition in force for the plan.
Carelon Medical Benefits Management	PA via Carelon (per plan)	Reviews BVNA under musculoskeletal/pain-management criteria aligned with the Modic-change, conservative-care, and level/frequency requirements of the Medicare LCDs.
TurningPoint Healthcare Solutions	PA via TurningPoint (per plan)	Manages BVNA for certain plans (for example, some Blue Cross Blue Shield programs); criteria track the LCD framework.

Back to page contents

15

Clinical Evidence

Evidence-Based Clinical and Specialty-Society Guidelines

The evidence base includes a sham-controlled randomized trial and a standard-care-controlled randomized trial, with published durability follow-up. The source guide characterizes the evidence as moderate quality for carefully selected adults with chronic vertebrogenic pain and Type 1 or Type 2 Modic changes. Clinical evidence supports patient selection; it does not replace the controlling payer policy.

Clinical evidence is not payer policy

Use trials, systematic reviews, and specialty-society statements to support patient selection and peer-to-peer discussion. Coverage still depends on the applicable benefit plan, payer policy, MAC jurisdiction, and effective date.

Key clinical evidence and society resources

• Fischgrund JS, Rhyne A, Franke J, et al. Intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: a prospective randomized double-blind sham-controlled multicenter study (SMART). Eur Spine J. 2018;27(5):1146-1156.
• Fischgrund JS, Rhyne A, Franke J, et al. Intraosseous basivertebral nerve ablation: 2-year results from a prospective randomized double-blind sham-controlled multicenter study. Int J Spine Surg. 2019;13(2):110-119.
• Fischgrund JS, Rhyne A, Macadaeg K, et al. Long-term outcomes following intraosseous basivertebral nerve ablation: 5-year treatment-arm results. Eur Spine J. 2020;29(8):1925-1934.
• Khalil JG, Smuck M, Koreckij T, et al. A prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain (INTRACEPT). Spine J. 2019;19(10):1620-1632.
• Conger A, Schuster NM, Cheng DS, et al. The effectiveness of intraosseous basivertebral nerve radiofrequency neurotomy for chronic low back pain in patients with Modic changes: a systematic review. Pain Med. 2021;22(5):1039-1054.
• North American Spine Society (NASS) and International Pain & Spine Intervention Society (IPSIS). Coverage and coding resources. https://www.spine.org | https://www.ipsismed.org

Back to page contents

16

Policy Comparison

Policy and Guideline Comparison Matrix

This comparison separates the controlling Medicare pathway from commercial payer and delegated utilization-management review. Policy editions, products, jurisdictions, and delegation arrangements change; verify the live source for the member and date of service.

Medicare comparison point

CMS has no procedure-specific National Coverage Determination for intraosseous basivertebral nerve ablation. Medicare coverage is therefore controlled by the applicable Medicare Administrative Contractor, the effective Local Coverage Determination, and its companion Billing and Coding Article for the beneficiary's jurisdiction and date of service.

Payer / Vendor	PA Pathway	Representative Position (verify current policy)
eviCore (Cigna and delegated plans)	PA via eviCore MSK	BVNA is reviewed under eviCore's musculoskeletal guidelines; eviCore's ablation/denervation guidance (CMM-208, Ablation/Denervation of Joints and Peripheral Nerves; a V1.0.2026 edition effective 08/04/2026) addresses basivertebral nerve ablation. Confirm the specific guideline and edition in force for the plan.
Carelon Medical Benefits Management	PA via Carelon (per plan)	Reviews BVNA under musculoskeletal/pain-management criteria aligned with the Modic-change, conservative-care, and level/frequency requirements of the Medicare LCDs.
TurningPoint Healthcare Solutions	PA via TurningPoint (per plan)	Manages BVNA for certain plans (for example, some Blue Cross Blue Shield programs); criteria track the LCD framework.
UnitedHealthcare	PA per plan; MA adopts LCD	UnitedHealthcare Medicare Advantage applies the Noridian LCDs (L39642/A59466, L39644/A59468); commercial coverage is governed by the applicable medical policy.
Aetna	PA / precertification per plan	CPB 0016 (Back Pain: Invasive Procedures) addresses the Intracept System (intraosseous basivertebral nerve ablation). Aetna's determination has been evolving; verify the current medically-necessary versus experimental status for the indication.
Blue Cross Blue Shield plans	PA per plan; some vendor-managed	Multiple BCBS plans cover BVNA for patients 18 and older meeting Modic-change and conservative-care criteria, with lifetime caps mirroring Medicare (for example, no more than 4 vertebral bodies per lifetime; treatment of 3 or more bodies in one session and retreatment of a previously treated body may be deemed investigational or not medically necessary).
Humana	PA per plan / MA	Covers BVNA for qualifying vertebrogenic pain; MA plans apply the applicable LCD and internal coverage policy.

Back to page contents

17

Prior Authorization

Prior Authorization Requirements

A complete BVNA authorization package should identify the delegated reviewer, quote the MRI Modic type and endplate level, document at least six months of failed non-surgical management, exclude a dominant radicular or stenotic pain source, identify the requested vertebral bodies and CPT structure, and confirm session and lifetime capacity. After approval, the authorization number, approved levels, setting, and validity window must match the scheduled service and claim.

Authorization-to-claim integrity

Confirm that the approved code, level, units, site of service, servicing provider, authorization period, and planned procedure match the service that will be performed and billed.

Back to page contents

18

Documentation

Documentation Requirements

Use this as a pre-submission and pre-claim gate. Every item present converts most BVNA requests into first-pass approvals and supports the KX attestation on Medicare claims.

• Chronic axial-dominant low back pain of at least 6 months documented
• Vertebrogenic pain pattern (axial, midline, worse with sitting/loading) described
• Failed conservative care: at least 6 months and at least 3 modalities, with outcomes
• MRI report language identifying Type 1 or Type 2 Modic changes at the endplate level
• Treated level(s) confined to L3-S1 and correlated with imaging
• Competing pain generators (radicular, stenotic, deformity, fracture, tumor, infection) excluded
• Skeletal maturity (18 or older) confirmed
• Physical and psychological ability to benefit assessed
• Lifetime treated-body count and session-level count within limits (<= 4 lifetime, <= 2 per session)
• No prior ablation of the same named vertebral body
• Level-specific medical-necessity statement present
• KX modifier support documented (Medicare); modifier 52 noted if single-body ablation
• Authorization number, approved levels, setting (ASC/HOPD), and validity window on file

Back to page contents

19

Documentation

Documentation Pearls

Drawn from GoHealthcare's experience supporting musculoskeletal specialty practices, these operational patterns most reliably improve approval rates and reduce rework for BVNA.

• Quote the Modic finding verbatim. The MRI report language identifying Type 1 or Type 2 Modic changes at the endplate level is the single most decisive element; paraphrasing it loosely is the most common cause of an otherwise-strong pend.

• Enumerate the conservative-care trial. State the duration (at least 6 months) and list the specific modalities with outcomes; a vague history is the second most common denial.
• Rule out the radicular/stenotic mimic. Affirmatively documenting that pain is axial and vertebrogenic (not radicular or claudicatory) forecloses the most frequent clinical objection.
• Run the lifetime-count check. Track treated bodies across time so a request never exceeds the 4-body lifetime cap or retreats a previously ablated body.

Pearls

• A quoted Modic finding plus an enumerated 6-month conservative-care trial resolves most BVNA pends.
• Affirmatively excluding radicular/stenotic pain establishes the vertebrogenic source reviewers require.
• A lifetime ledger prevents the frequency-cap and retreatment denials that are otherwise easy to miss.

Pitfalls

• Unspecified diagnosis coding (M54.50) that undercuts medical necessity.
• Non-billable differential codes (M48.06) instead of the specific stenosis codes.
• Reflexive KX application without the underlying documentation - a compliance exposure.

Back to page contents

20

Coding

CPT and HCPCS Coding

This overview is operational, not a reimbursement-methodology treatment. Fee schedules, NCCI edit tables, MUE values, and payment rates belong to the GoHealthcare Revenue Cycle Knowledge Center. The coding fundamentals below drive clean BVNA claims.

• Report 64628 for the first two vertebral bodies (a motion segment) and one unit of +64629 for each additional vertebral body.
• Image guidance (fluoroscopy 77003; CT 77012) is included and is not separately reportable.
• Medicare requires the KX modifier on the covered code to attest that all LCD requirements are met.
• If only a single endplate exhibits Modic changes and only one vertebral body is ablated, report 64628 with modifier 52 (reduced services) and document what was reduced.
• Observe MUE limits (commonly 1 unit for 64628 and 2 units for 64629) and the LCD session limit of no more than 2 levels.
• Place of service is typically ASC (24) or hospital outpatient (19/22); the RF probe and access instruments are packaged into the facility payment (BVNA is a device-intensive procedure under OPPS).
• M54.51 (vertebrogenic low back pain) is the diagnosis that supports the service.

CPT(R)	Descriptor (abbreviated)	Coding Notes
64628	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral	Primary code; reported once for the first two treated bodies (a motion segment). Effective 01/01/2022 (replaced Category III 0656T). MUE commonly 1.

CPT(R)	Descriptor (abbreviated)	Coding Notes
+64629	Same; each additional vertebral body, lumbar or sacral (list separately in addition to primary)	Add-on for each additional body; must accompany 64628 and cannot be reported alone. MUE commonly 2. Do not append modifier 51.
77003 / 77012	Fluoroscopic / CT guidance	Bundled into 64628/64629 - not separately reportable.

Historical note. Category III codes 0656T/0657T were used before 01/01/2022 and are obsolete for current dates of service.

No distinct HCPCS Level II code is required to report the physician (professional) service for BVNA; the CPT codes above capture the work. Device-related considerations arise in the facility setting:

• The radiofrequency probe, generator, and access instruments are packaged into the facility payment (OPPS APC for HOPD; the ASC payment for ASC) rather than separately billed; BVNA is treated as a device-intensive procedure under OPPS.
• Because packaging rules and any pass-through status change annually, verify device coding against the current CMS OPPS/ASC files rather than carrying forward prior-year assumptions.

Back to page contents

21

Diagnosis Coding

ICD-10-CM Crosswalk

BVNA is supported by a single principal diagnosis, with several codes serving as differentials that must be excluded (and that, if dominant, render BVNA non-covered). Code to the highest documented specificity. Verify against the current MAC article's covered-diagnosis list.

ICD-10-CM	Description	Role in BVNA
M54.51	Vertebrogenic low back pain	Principal covered diagnosis; effective 10/01/2021 (part of the M54.5 split). Requires MRI Modic Type 1 or 2 support; alone it does not establish necessity - the record must document the criteria.
G89.29	Other chronic pain	May be reported secondarily to characterize chronicity when supported by documentation.
M54.50 / M54.59	Low back pain, unspecified / Other low back pain	Non-specific; do not substitute for M54.51 when a vertebrogenic source is documented.
M54.16	Radiculopathy, lumbar region	Differential to exclude; if radicular pain is dominant, BVNA is not indicated/covered.
M48.061 / M48.062	Spinal stenosis, lumbar region without / with neurogenic claudication	Differential to exclude; note 5th/6th-digit specificity (M48.06 is not billable). Symptomatic stenosis/neurogenic claudication is a non-covered indication.
M51.36	Other intervertebral disc degeneration, lumbar region	Differential; discogenic pathology is a distinct entity from endplate-driven vertebrogenic pain.
M54.30 / M54.31 / M54.32	Sciatica, unspecified / right / left side	Differential to exclude; sciatica indicates a non-vertebrogenic, radicular pattern.

GoHealthcare Coding Insight

The most common BVNA coding pitfalls are (1) defaulting to M54.50 (unspecified) when the record actually supports M54.51 (vertebrogenic), which weakens medical necessity, and (2) using a non-billable stenosis parent code (M48.06) instead of the specific M48.061/M48.062 when documenting an excluded differential. Both are avoidable with a brief coder check.

Back to page contents

22

Billing Integrity

Billing Integrity: Modifiers, Units, NCCI, MUE, and Place of Service

Modifier	Use	Notes
KX (Medicare)	Required attestation	Append to the covered code to attest that all LCD requirements (Modic changes, conservative-care failure, level, and lifetime/session limits) are met and documented.
52 (reduced services)	Single-body / single-endplate ablation	Append to 64628 when only one vertebral body (one endplate) is treated; document what was reduced.
51 (multiple procedures)	Do not append to +64629	Add-on codes are exempt from multiple-procedure reduction and from modifier 51.
59 / X{EPSU}	Rarely applicable	Do not use to bypass session or bundling rules; BVNA may not be combined with facet/epidural interventions in the same session.
22 (increased procedural services)	Situational	Only with documentation substantiating significantly increased work; expect manual review.

This overview is operational, not a reimbursement-methodology treatment. Fee schedules, NCCI edit tables, MUE values, and payment rates belong to the GoHealthcare Revenue Cycle Knowledge Center. The coding fundamentals below drive clean BVNA claims.

• Report 64628 for the first two vertebral bodies (a motion segment) and one unit of +64629 for each additional vertebral body.
• Image guidance (fluoroscopy 77003; CT 77012) is included and is not separately reportable.
• Medicare requires the KX modifier on the covered code to attest that all LCD requirements are met.
• If only a single endplate exhibits Modic changes and only one vertebral body is ablated, report 64628 with modifier 52 (reduced services) and document what was reduced.
• Observe MUE limits (commonly 1 unit for 64628 and 2 units for 64629) and the LCD session limit of no more than 2 levels.
• Place of service is typically ASC (24) or hospital outpatient (19/22); the RF probe and access instruments are packaged into the facility payment (BVNA is a device-intensive procedure under OPPS).
• M54.51 (vertebrogenic low back pain) is the diagnosis that supports the service.

Back to page contents

23

Reimbursement

Reimbursement Considerations

Report the professional service with 64628 for the first two treated lumbar or sacral vertebral bodies and +64629 for each additional body when supported. Imaging guidance is included. In the facility setting, the radiofrequency probe, access instruments, and related device costs are generally packaged into the applicable ASC or hospital outpatient payment. Medicare claims require the KX modifier only when the record supports every applicable LCD criterion. Verify current OPPS, ASC, MUE, NCCI, and payer-contract rules before billing.

Authorization does not guarantee payment

Payment remains subject to eligibility, benefit design, coding accuracy, medical necessity, contract terms, claim edits, site of service, and the payer policy in effect on the date of service.

Back to page contents

24

Denial Management

Denial Prevention

• Adopt a structured BVNA intake form capturing Modic type/level, conservative-care duration and modalities, vertebrogenic pattern, and lifetime-count check before submission.
• Require the MRI report (not just the order) and quote the Modic language in the clinical note.
• Code M54.51 when the record supports a vertebrogenic source; reserve M54.50 for truly unspecified pain.
• Maintain a per-patient lifetime ledger of treated vertebral bodies to prevent cap breaches and retreatment.
• Gate the KX modifier behind a completed documentation checklist.
• Confirm the planned device system is recognized by the payer's current policy edition, especially for newer entrants.

Back to page contents

25

Denial Management

Common Denial Reasons

Denial Rationale	Root Cause	Prevention
No documented Modic changes	MRI report does not state Type 1 or Type 2 Modic changes at the treated level	Quote the MRI language identifying Modic type and endplate level (L3-S1).
Insufficient conservative care	Duration or modality count not documented (under 6 months or under 3 modalities)	Enumerate at least 6 months and at least 3 modalities with outcomes.
Non-vertebrogenic pain source	Radiculopathy, stenosis, or neurogenic claudication appears dominant	Affirmatively exclude competing generators and confirm axial-dominant, vertebrogenic pain.
Level outside L3-S1	Requested level not covered	Confirm treatment is confined to L3 through S1.
Frequency limit exceeded	More than 2 levels per session, more than 4 bodies lifetime, or retreatment of a prior body	Track lifetime treated bodies; keep sessions to 2 levels; do not retreat a previously ablated body.
Combined with facet/epidural same session	BVNA billed with another paravertebral intervention on the same date	Separate BVNA from facet/epidural procedures by session.
Missing KX modifier (Medicare)	Attestation of LCD compliance not affixed	Append KX only when every LCD requirement is documented.

Back to page contents

26

Appeals

Appeals, Reconsideration, and Peer-to-Peer

BVNA denials are almost always missing-criteria denials. Effective appeals supply the specific element the policy requires rather than re-arguing the therapy.

• Lead with the Modic finding: quote the MRI report identifying Type 1 or Type 2 Modic changes at the specific L3-S1 level.
• Document the conservative-care trial explicitly: at least 6 months, at least 3 modalities, with outcomes.
• Affirmatively exclude radicular/stenotic pain to establish a vertebrogenic source.
• Confirm the level and the lifetime/session counts are within limits.
• Attach the specific LCD or policy criterion satisfied and map the record to each element.
• Prepare the physician for a peer-to-peer focused on the Modic finding, the conservative-care duration, and the vertebrogenic pattern.

GoHealthcare Best Practices

Because BVNA criteria are so explicit, a single structured intake form that forces the Modic type, the endplate level, the conservative-care duration, and the lifetime-count check into every request eliminates the large majority of denials before they occur.

Back to page contents

27

Operations

Operational Workflow

This workflow runs from evaluation through scheduling and post-service coding. Traditional Medicare omits pre-service authorization but requires the same substantiation plus the KX modifier on the claim.

• 1. Evaluation and imaging: establish the vertebrogenic pain pattern, obtain MRI documenting Type 1 or Type 2 Modic changes at L3-S1, and exclude competing pain generators.
• 2. Conservative-care verification: confirm and document at least 6 months of failed non-surgical management across the required modalities.
• 3. Benefit and vendor check: identify the plan, the adjudicating vendor (eviCore, Carelon, or TurningPoint), and the applicable policy edition; confirm remaining lifetime/session capacity.
• 4. Clinical assembly: compile the MRI report language (Modic type and level), the conservative-care history, the vertebrogenic pattern, and the level-specific medical-necessity statement.
• 5. Submission: submit with the planned CPT/level detail (64628 and any +64629 levels) and M54.51 as the linked diagnosis.
• 6. Clinical review / peer-to-peer: if pended, supply the missing element (most often the Modic finding or the conservative-care duration); prepare the physician for a focused peer-to-peer.
• 7. Determination and scheduling: record the authorization number, approved level(s), and validity window; schedule within the authorized period and setting (ASC vs HOPD).
• 8. Post-service: code one primary plus add-on levels, append the KX modifier on Medicare claims, and ensure the record supports the lifetime/session limits.

Back to page contents

28

Reviewer Lens

Payer Perspective

Payer Perspective

A reviewer is likely to test four points first: documented Type 1 or Type 2 Modic change at L3-S1, at least six months of failed non-surgical management, a vertebrogenic rather than radicular or stenotic pain pattern, and compliance with level, session, and lifetime limits. Missing one of these elements commonly results in a pend or denial even when the patient may otherwise be clinically appropriate.

Back to page contents

29

Clinical Pearls

Clinical Pearls

Pearls

• A quoted Modic finding plus an enumerated 6-month conservative-care trial resolves most BVNA pends.
• Affirmatively excluding radicular/stenotic pain establishes the vertebrogenic source reviewers require.
• A lifetime ledger prevents the frequency-cap and retreatment denials that are otherwise easy to miss.

Pitfalls

• Unspecified diagnosis coding (M54.50) that undercuts medical necessity.
• Non-billable differential codes (M48.06) instead of the specific stenosis codes.
• Reflexive KX application without the underlying documentation - a compliance exposure.

Back to page contents

30

GoHealthcare Perspective

GoHealthcare Perspective

GoHealthcare Leadership Perspective

BVNA is a criteria-dense procedure, which makes it a clean test of an organization's ability to operationalize a coverage policy. The programs that succeed convert the LCD's discrete requirements - Modic type, endplate level, conservative-care duration, lifetime count - into structured intake fields rather than relying on narrative prose. The KX modifier deserves particular governance attention. It is an affirmative attestation of compliance, so it should be driven by a documentation checklist rather than applied reflexively; appending KX without the underlying record is a compliance exposure, not a billing convenience. As the device market diversifies (Intracept, OptaBlate, ViaVerte), coverage remains largely procedure-based, but policy language and payer recognition of newer systems will evolve. AI-enabled review that checks for the Modic statement, the conservative-care duration, the level, and the lifetime-count before submission turns a demanding policy into a repeatable workflow.

Back to page contents

31

GoHealthcare Insights

GoHealthcare Insights

Drawn from GoHealthcare's experience supporting musculoskeletal specialty practices, these operational patterns most reliably improve approval rates and reduce rework for BVNA.

• Quote the Modic finding verbatim. The MRI report language identifying Type 1 or Type 2 Modic changes at the endplate level is the single most decisive element; paraphrasing it loosely is the most common cause of an otherwise-strong pend.

• Enumerate the conservative-care trial. State the duration (at least 6 months) and list the specific modalities with outcomes; a vague history is the second most common denial.
• Rule out the radicular/stenotic mimic. Affirmatively documenting that pain is axial and vertebrogenic (not radicular or claudicatory) forecloses the most frequent clinical objection.
• Run the lifetime-count check. Track treated bodies across time so a request never exceeds the 4-body lifetime cap or retreats a previously ablated body.

GoHealthcare Prior Authorization Insight

From the vantage point of a national MSK specialty MSO, BVNA is one of the most criteria-driven procedures in the pain portfolio, and virtually every failure traces to a specific missing element rather than a genuine coverage dispute.

What experienced PA teams do differently

• They lead the request with the quoted Modic finding and the endplate level.
• They enumerate the 6-month, 3-modality conservative-care trial with outcomes.
• They affirmatively exclude radicular and stenotic pain to establish a vertebrogenic source.
• They maintain a running lifetime-count ledger so no request exceeds 4 bodies or retreats a body.
• They gate the KX modifier behind a completed documentation checklist.

Frequent provider mistakes

• Ordering MRI but not stating the Modic type/level in the clinical note.
• A conservative-care history that omits duration or modality count.
• Coding M54.50 (unspecified) when M54.51 (vertebrogenic) is supported.
• Requesting more than 2 levels per session or exceeding the 4-body lifetime cap.
• Appending KX without the supporting documentation in the record.

Back to page contents

32

FAQ

Frequently Asked Questions

What condition does BVNA treat?

Chronic vertebrogenic low back pain - pain originating from degenerated vertebral endplates, evidenced by Type 1 or Type 2 Modic changes on MRI. It does not treat fractures, disc herniation, or facet pain.

What are Modic changes and why do they matter?

Modic changes are MRI signal changes at the vertebral endplates/marrow. Type 1 is inflammatory/edematous and Type 2 is fatty. Type 1 or Type 2 changes at L3-S1 are the decisive coverage criterion for BVNA.

Which CPT codes are used?

64628 for the first two vertebral bodies (a motion segment) and +64629 for each additional vertebral body. Image guidance is bundled.

When did the current codes take effect?

64628 and 64629 became effective January 1, 2022, replacing Category III codes 0656T and 0657T.

What is the KX modifier and when is it used?

For Medicare, the KX modifier is appended to the covered code to attest that all LCD requirements (Modic changes, conservative-care failure, level, and frequency limits) are met and documented.

How many levels can be treated in one session?

No more than two vertebral levels per session under the Medicare LCDs.

What is the lifetime limit?

Treatment is limited to L3-S1, once per named vertebral body, with no more than four vertebral bodies per beneficiary per lifetime; a previously ablated body cannot be retreated.

What levels are covered?

Only the L3 through S1 vertebral bodies.

How much conservative care is required?

Generally at least 6 months of failed non-surgical management, typically spanning at least three modalities, documented with outcomes.

What ICD-10 code supports BVNA?

M54.51 (vertebrogenic low back pain), effective October 1, 2021. It requires MRI Modic support and does not, by itself, establish medical necessity.

Can BVNA be combined with a facet or epidural procedure the same day?

No. The LCDs specify BVNA may not be combined with any other paravertebral injection or intervention (facet or epidural) in the same session.

Is image guidance billed separately?

No. Fluoroscopic (77003) and CT (77012) guidance are bundled into 64628/64629.

What if only one vertebral body (one endplate) is treated?

Report 64628 with modifier 52 (reduced services) and document what was reduced.

Is BVNA covered for radicular or stenotic pain?

No. Dominant radicular pain, symptomatic stenosis, and neurogenic claudication are non-covered; the pain must be vertebrogenic.

Is BVNA covered for patients under 18?

No. Skeletal immaturity (under 18) is a non-covered condition.

Does BVNA leave an implant or affect future MRI?

No. BVNA is implant-free; there is no device-related MRI conditionality, and the treated vertebra remains available for future imaging.

Which device systems are available?

The Intracept Procedure (Boston Scientific, formerly Relievant) is the established system; Stryker OptaBlate BVN (FDA cleared May 2025) and Merit Medical ViaVerte (distributed by Medtronic) are newer entrants. Coverage is generally procedure-based.

Who manages commercial prior authorization?

Frequently eviCore (under CMM-208), Carelon, or TurningPoint, depending on the plan.

Does traditional Medicare require prior authorization?

Not for the professional service, but the LCD criteria are enforced at adjudication and on audit, and the KX modifier attestation is required.

What is the strongest evidence for BVNA?

The sham-controlled SMART RCT (Fischgrund, Eur Spine J 2018) with 2- and 5-year durability, and the standard-care-controlled INTRACEPT RCT (Spine J 2019).

What is the single best way to avoid a peer-to-peer?

Quote the Modic finding and enumerate the 6-month conservative-care trial in the first paragraph of the request, and confirm the level and lifetime/session counts.

Back to page contents

33

Case Study

GoHealthcare Case Study

Educational scenario. No actual patient or organization is depicted.

Clinical scenario

A pain practice requests BVNA at L4 and L5 for an adult with two years of deep, midline, axial low back pain worse with sitting and forward flexion. MRI reports Type 2 Modic changes at the L4-L5 endplates. The patient has completed physical therapy, a home exercise program, pharmacotherapy, and a prior epidural injection over more than a year.

Documentation challenges

The initial request stated 'chronic low back pain' with a diagnosis of M54.50, did not quote the Modic finding, and summarized conservative care as 'failed multiple treatments' without duration or a modality list.

Prior authorization barriers

The delegated vendor pended the request for absent Modic documentation, an unspecified diagnosis, and an inadequately documented conservative-care trial, and offered a peer-to-peer.

Payer considerations

The policy required MRI Type 1 or Type 2 Modic changes at L3-S1, at least 6 months of failed conservative care, exclusion of radicular/stenotic pain, and treatment confined to two levels within lifetime limits.

Operational workflow & resolution strategy

The MSO's PA team resubmitted with the MRI report language quoting Type 2 Modic changes at L4-L5, the diagnosis corrected to M54.51, an enumerated conservative-care trial (PT, home exercise, pharmacotherapy, and epidural injection over 14 months with outcomes), and an explicit statement excluding radicular and stenotic pain. The lifetime ledger confirmed no prior ablation and only two levels this session.

Outcome

The request was approved without a peer-to-peer. The claim coded as 64628 for L4-L5 with the KX modifier appended and M54.51 linked.

Lessons learned

• The clinical facts already met criteria; the diagnosis code and documentation packaging were the gap.
• Correcting M54.50 to M54.51 and quoting the Modic finding resolved the core objections.
• The enumerated conservative-care trial and the lifetime-count check supported the KX attestation.

Back to page contents

34

Related Resources

Related Procedures and Resources

The table contrasts BVNA with adjacent options for chronic low back pain. It is an operational comparison, not a treatment recommendation.

Option	Target / Mechanism	Primary CPT	Typical Role
Basivertebral nerve ablation	Ablates the intraosseous basivertebral nerve; treats vertebrogenic (endplate) pain	64628 / +64629	Chronic vertebrogenic low back pain with Type 1/2 Modic changes at L3-S1 after failed conservative care.
Facet (medial branch) radiofrequency ablation	Ablates medial branch nerves; treats facet joint pain	64635 / +64636 (lumbar)	Facet-mediated pain confirmed by diagnostic blocks; a different pain generator (companion facet guide).
Epidural steroid injection	Reduces inflammation around nerve roots	62322/62323, 64483/+64484	Radicular pain; not a treatment for vertebrogenic endplate pain.
Vertebroplasty / Kyphoplasty	Stabilizes a fractured vertebral body with cement	22510-22515	Painful vertebral compression fracture - a different indication entirely (companion guides).
Conservative management	Activity modification, PT, pharmacotherapy	N/A	The required 6-month prerequisite against which BVNA medical necessity is judged.

• GoHealthcare MSK Specialty Procedure Library - Kyphoplasty (companion guide).
• GoHealthcare MSK Specialty Procedure Library - Vertebroplasty (companion guide).
• GoHealthcare MSK Specialty Procedure Library - Facet Joint Interventions and Radiofrequency Ablation (related batch).
• GoHealthcare Revenue Cycle Knowledge Center - OPPS/ASC packaging, device-intensive procedure handling, NCCI, and MUE reference.
• GoHealthcare Prior Authorization Playbooks - Modic-change and conservative-care templates; lifetime-count ledger.
• Website: https://www.gohealthcarellc.com

Back to page contents

35

References

References and Reading Recommendations

• Centers for Medicare & Medicaid Services. Medicare Coverage Database (LCDs, LCAs, NCDs). https://www.cms.gov/medicare-coverage-database
• CMS / Noridian. LCD: Intraosseous Basivertebral Nerve Ablation (L39642, L39644) and Billing and Coding Articles (A59466,
• American Medical Association. Current Procedural Terminology (CPT(R)) 2026. https://www.ama-assn.org/practice-management/cpt
• eviCore by Evernorth. Clinical Guideline CMM-208: Ablation/Denervation of Joints and Peripheral Nerves. https://www.evicore.com/provider/clinical-guidelines
• Carelon Medical Benefits Management. Musculoskeletal / Pain Management Clinical Guidelines. https://www.carelonmedicalbenefitsmanagement.com
• Aetna. Clinical Policy Bulletin 0016: Back Pain - Invasive Procedures. https://www.aetna.com/cpb/medical/data/1_99/0016.html
• Fischgrund JS, Rhyne A, Franke J, et al. Intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: a prospective randomized double-blind sham-controlled multicenter study (SMART). Eur Spine J. 2018;27(5):1146-1156.
• Fischgrund JS, Rhyne A, Franke J, et al. Intraosseous basivertebral nerve ablation: 2-year results from a prospective randomized double-blind sham-controlled multicenter study. Int J Spine Surg. 2019;13(2):110-119.
• Fischgrund JS, Rhyne A, Macadaeg K, et al. Long-term outcomes following intraosseous basivertebral nerve ablation: 5-year treatment-arm results. Eur Spine J. 2020;29(8):1925-1934.
• Khalil JG, Smuck M, Koreckij T, et al. A prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain (INTRACEPT). Spine J. 2019;19(10):1620-1632.
• Conger A, Schuster NM, Cheng DS, et al. The effectiveness of intraosseous basivertebral nerve radiofrequency neurotomy for chronic low back pain in patients with Modic changes: a systematic review. Pain Med. 2021;22(5):1039-1054.
• U.S. Food & Drug Administration. 510(k) Premarket Notification Database. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
• Boston Scientific. Intracept Intraosseous Nerve Ablation System - Indications, Safety, and Instructions for Use. https://www.bostonscientific.com
• Stryker. OptaBlate BVN Basivertebral Nerve Ablation System (FDA 510(k) clearance, May 2025). https://www.stryker.com
• North American Spine Society (NASS) and International Pain & Spine Intervention Society (IPSIS). Coverage and coding resources. https://www.spine.org | https://www.ipsismed.org

• The applicable Noridian LCD (L39642 or L39644) and Billing/Coding Article (A59466 or A59468) for the patient's jurisdiction and date of service.
• The effective-dated commercial policy in force for the specific plan (eviCore CMM-208, the applicable BCBS policy, Carelon, or TurningPoint criteria).
• The pivotal SMART and INTRACEPT trials and the Conger systematic review for peer-to-peer preparation.
• The device manufacturer's current instructions-for-use and coding/payment guide for the specific system planned (Intracept, OptaBlate, or ViaVerte).

Back to page contents

36

Disclaimer

Standard Disclaimer

Educational and Operational Disclaimer

This document is intended for educational and operational reference purposes only. It does not replace physician clinical judgment, payer policy review, legal advice, or official CMS guidance. Coverage policies, coding guidance, and reimbursement requirements should always be verified with the applicable payer and current regulatory sources before a claim is submitted. Procedure-specific technique, device selection, and patient care decisions remain the responsibility of the treating physician.

Developed by

Pinky Maniri

Founder and Chief Executive Officer, GoHealthcare Practice Solutions

Healthcare operations, MSK prior authorization, revenue-cycle strategy, compliance, and healthcare AI governance.

View LinkedIn Profile

Strengthen Authorization, Documentation, and Revenue Integrity

GoHealthcare supports MSK practices, spine programs, ASCs, and healthcare organizations with payer-policy interpretation, prior authorization, utilization management, documentation improvement, coding, denial prevention, appeals, and operational workflow design.

Request HelpView Case Study Library